Exemestane in early breast cancer: a review

Exemestane in early breast cancer: a review

Michael Untch1, Christian Jackisch21Interdisciplinary Breast Centre, Helios Klinikum Berlin-Buch, University Charit&eacute;, Berlin, Germany; 2Department of Gynecology/Obstetrics, Klinikum Offenbach GmbH, Offenbach, GermanyAbstract: The adjuvant treatment of women with endocrine-sensitive ea...

Full description

Bibliographic Details
Main Authors:	Michael Untch, Christian Jackisch
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-12-01
Series:	Therapeutics and Clinical Risk Management
Online Access:	http://www.dovepress.com/exemestane-in-early-breast-cancer-a-review-a2701

Similar Items

A review of the use of exemestane in early breast cancer
by: Andrew Robinson
Published: (2008-12-01)

Exemestane: A milestone against breast cancer
by: Shetty Y, et al.
Published: (2007-01-01)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
by: Muaiad Kittaneh, et al.
Published: (2011-10-01)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
by: Muaiad Kittaneh, et al.
Published: (2011-01-01)

Long-term efficacy and safety of exemestane in the treatment of breast cancer
by: Walker GA, et al.
Published: (2013-03-01)

Clinical utility of exemestane in the treatment of breast cancer 
by: Zucchini G, et al.
Published: (2015-05-01)

Apoptosis and autophagy in breast cancer cells following exemestane treatment.
by: Cristina Amaral, et al.
Published: (2012-01-01)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2019-09-01)

Methylome Variation Predicts Exemestane Resistance in Advanced ER Breast Cancer
by: Xiao-ran Liu PhD, et al.
Published: (2020-03-01)

Methotrexate-Lactoferrin Targeted Exemestane Cubosomes for Synergistic Breast Cancer Therapy
by: Bekhit, A.A, et al.
Published: (2022)

Exemestane in the prevention setting
by: Jennifer Keating Litton, et al.
Published: (2012-05-01)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
by: Gabriel N. Hortobagyi
Published: (2015-03-01)

Aromatase inhibitors in breast cancer: Signaling pathways involved in exemestane-acquired resistance
by: Tiago André Sousa Vieira Augusto
Published: (2019)

Antiproliferative effect of exemestane in lung cancer cells
by: Giannopoulou Efstathia, et al.
Published: (2009-01-01)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
by: Claudia Omarini, et al.
Published: (2018-01-01)

Triggering of Suicidal Erythrocyte Death by Exemestane
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2017-05-01)

Subepithelial Corneal Deposits Associated with Exemestane
by: Annahita Amireskandari, et al.
Published: (2020-01-01)

Determination of Exemestane in bulk and pharmaceutical dosage form by HPTLC
by: Maya B. Mane, et al.
Published: (2014-09-01)

Characterization and Pharmacogenetics of Hepatic Phase I Exemestane Metabolism
by: Peterson, Amity
Published: (2017)

Early Changes of the Standardized Uptake Values (SUV<sub>max</sub>) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Marianna Sirico, et al.
Published: (2020-11-01)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01)

Analytical Method Development and Validation of Exemestane Tablet by UV Spectrophotometry
by: S. Angalaparameswari, et al.
Published: (2012-01-01)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
by: Katsuhiko Nakatsukasa, et al.
Published: (2021-01-01)

Development and evaluation of exemestane-loaded lyotropic liquid crystalline gel formulations
by: Muhammad Nuh Musa, et al.
Published: (2017-09-01)

Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
by: Berna Öksüzoğlu, et al.
Published: (2020-06-01)

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases
by: J. Thaddeus Beck, et al.
Published: (2015-02-01)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
by: Dinja T. Kruger, et al.
Published: (2020-03-01)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020-06-01)

Crystal engineering of exemestane to obtain a co-crystal with enhanced urease inhibition activity
by: Syeda Saima Fatima, et al.
Published: (2020-01-01)

Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers
by: Hande Beklen, et al.
Published: (2021-09-01)

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
by: Peyman Hadji, et al.
Published: (2019-02-01)

Prolonged response to exemestane following multiple surgical resections and hormonal therapies in a patient with recurrent endometrial stromal sarcoma
by: Heather Wolfe, et al.
Published: (2016-01-01)

Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
by: Christian Jackisch, et al.
Published: (2014-09-01)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
by: Peter Schmid, et al.
Published: (2021-01-01)

A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines
by: Shailima Rampogu, et al.
Published: (2020-06-01)

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
by: Guenther G. Steger, et al.
Published: (2020-04-01)

Effectiveness of the aromatase (P450 Arom) inhibitors Letrozole and Exemestane for masculinization of red tilapia (Oreochromis spp.)
by: John J Betancur López, et al.
Published: (2014-03-01)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
by: Patricia A. Young, MD, et al.
Published: (2021-04-01)

Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10
by: Ya-Hui Wang, et al.
Published: (2017-01-01)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2018-07-01)